Fate Therapeutics, Inc.

Based on SEC filings and company reports, Fate Therapeutics generates revenue primarily from collaboration agreements and research activities related to its cell therapy programs. These activities involve the development of novel therapeutic approaches using cellular immunotherapy, which are halal activities. No revenue is derived from haram sources such as alcohol, gambling, or other prohibited activities.

The company is still in its pre-revenue/R&D phase, primarily focused on developing its therapeutic candidates. Over the past four quarters, the company has reported no interest income or interest expense. Given the company's pre-revenue status and R&D focus, we skip the interest ratio calculations as they would not reflect the company's mature operating state.

Based on available information from SEC filings and company materials, there is no evidence of significant ongoing associations with entities involved in human rights violations. The company's operations and research facilities are primarily based in the United States, with no identified R&D centers or significant operations in Israel or direct ties to the Chinese Communist Party.